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Abstract
A sensitive, accurate, and precise liquid chromatography–mass spectrometry assay for the
determination of tenofovir (TNF) in human vaginal tissue was developed and validated. After
homogenization of the tissue, solid-phase extraction on Varian Bond Elut-C18 column was used for
sample clean up. Chromatographic separation of TNF and the internal standard (tolbutamide) was
achieved with a Varian Polaris 3C18-A reversed-phase analytical column (150 mm × 2 mm). A
gradient method using 0.1% formic acid in water and 0.1% formic acid in acetonitrile was employed.
Detection of TNF and tolbutamide was achieved by electrospray ionization mass spectrometry in the
positive ion mode using 288.05 and 271.00 m/z, respectively. Linear TNF calibration curves were
obtained between 1–1,000 ng/mL with a correlation coefficient (r2) greater than 0.999. Intra-and
inter-day accuracy for TNF ranged from 89.7% and 109.4% and from 97.3% and 104.9%, and
precision ranged from 1.3% and 10.9% and 2.6% and 9.0%, respectively. This is the first validated
method developed to quantitate TNF in human tissues.
Introduction
Tenofovir (TNF) is the first nucleotide reverse transcriptase inhibitor approved by the U.S.
Food and Drug Administration for treatment of human immunodeficiency virus (HIV)-1 and
is used in combination with other antiviral medications to treat HIV infected patients (1). TNF
is a monophosphonate adenosine analogue (Figure 1) that is diphosphorylated to its active
moiety, TNF diphosphate (TNF-DP), within the cell where it functions as a competitive
inhibitor of reverse transcriptase and an HIV-DNA chain terminator.
Currently, a major effort is underway to develop pre-exposure prophylaxis strategies (PrEP)
against HIV infection, including oral and topical dosing of antiretroviral agents. One approach
currently in clinical study is the use of TNF, both with the oral dosing formulation (REF) and
as a 1% w/w topical gel (2). To understand the efficacy or failure of these approaches, it is
critical to understand the pharmacokinetics of TNF at the site of infection (namely, mucosal
tissues).
Several high-performance liquid chromatography (HPLC) or HPLC–tandem mass
spectrometry (MS–MS) methods have been developed and published to quantify TNF in
plasma (3–10). Yet, there is no known efficient method which can quantitate TNF in vaginal
tissue. It is believed that most of TNF will exist as diphosphate form in the tissue because
intracellular phosphorylation occurs very quickly. Therefore, we have developed a highly
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sensitive, accurate, and precise liquid chromatography–mass spectrometry (LC–MS) method




TNF was obtained from the NIH AIDS Research & Reference Reagent Program. Tolbutamide
was purchased from Sigma (St. Louis, MO). TNF-DP was kindly obtained from Gilead (Foster,
California). The structures of TNF and tolbutamide are shown in Figure 1. Formic acid, LC–
MS-grade acetonitrile, methanol, and ammonium acetate were purchased from Fisher
Scientific (Fairlawn, NJ). Phosphatase for enzymatic hydrolysis of TNF-DP was purchased
from Sigma. All other reagents were HPLC-grade. Purified compressed nitrogen gas was
purchased from National Welders Supply (Charlotte, NC).
Human vaginal tissue
Blank human vaginal tissue was obtained from the National Development and Research
Institute (NDRI) (New York, NY). In addition, six fresh vaginal tissue samples were obtained
from surgical waste at University of North Carolina Hospitals. All patients gave written
informed consent prior to donation. The tissue collection protocol was approved by the
institutional review board at the University of North Carolina at Chapel Hill. The tissues were
stored at −70°C in a freezer before analysis.
Instruments
The Shimadzu LC–MS consisted of Shimadzu LC–MS SIL-HTc autosampler, Shimadzu LC–
MS LC-20AD solvent delivery system, Shimadzu LC–MS 2010A MS Detector, and Shimadzu
LC–MS solution software (Tokyo, Japan). The analytical column was a Varian Polaris 3C18-
A (2 mm × 150 mm, Palo alto, CA) protected by a Phenomenex Polar RP guard cartridge
(Torrance, CA). A Fastprep-24 Homogenizer and Lysing Matrix A tubes for homogenization
of tissue were purchased from MP Biomedicals (Solon, Ohio).
Preparation of TNF, quality control, and internal standard solutions
Stock solutions of TNF and TNF-DP (as TNF) were prepared at a concentration of 1 mg/mL.
For TNF, 5.3 mg of TNF monohydrate (molecular weight 305.23 g) powder was accurately
weighed and dissolved in 3.0 mL of HPLC-grade water alkalinized with 50 μL of 5.0 M sodium
hydroxide solution, and the volume was adjusted to 5.0 mL using a 5.0-mL volumetric flask.
The TNF-DP stock solution was prepared by diluting 84.5 mM TNF-DP solution from Gilead
with HPLC-grade water to make 1 mg/mL solution. Further dilution with HPLC water was
used to prepare an intermediate stock solution for TNF and TNF-DP at a concentration of 100
μg/mL. This intermediate TNF stock solution was used to prepare seven working standard
solutions (1, 5, 10, 50, 100, 500, and 1000 ng/mL) in tissue homogenate. Tissue quality control
(QC) samples were prepared from a separately prepared intermediate 100 μg/mL stock to create
concentrations of 3, 150, and 750 ng/mL in tissue homogenate for both TNF and TNF-DP.
An internal standard stock solution was prepared by accurately weighing 5 mg of tolbutamide
and dissolving this in a volumetric flask with HPLC-grade water to achieve a final
concentration of 1.0 mg/mL. The internal standard (IS) working solution was prepared by
diluting an aliquot from the stock solution in 150 mM ammonium acetate buffer (pH adjusted
to 5.0 using 33% acetic acid) to a final concentration of 4.0 μg/mL.
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For calibrator and QC preparation, drug-free vaginal tissue was homogenized in a Lysing
matrix “A” tube using a Fastprep 24 homogenizer at a speed of 4 M/s for 60 s until the mixture
formed a homogeneous solution. Then, 200 μL of vaginal tissue homogenate (20 mg of tissue)
was mixed with 100 μL of working standard or QC solution, 50 μL of water and 50 μL of the
IS working solution.
For clinical sample preparation, 20 mg of tissue, 50 μL of IS working solution and 330 μL of
water were homogenized in a Lysing Matrix tube A using the Fastprep 24 homogenizer at a
speed of 4 M/s for 60 s until the mixture formed a homogeneous solution.
Enzymatic hydrolysis of TNF-DP in tissue
In tissue cells, phosphorylation occurs rapidly and most of TNF exists as a phosphorylated
form in the cell. To measure the total TNF concentration in tissue, an enzymatic hydrolysis
process using phosphatase is an essential step (9). An aliquot (20 μL) of homogenate was used
for another assay to measure protein content, and 50 μL of phosphatase solution (26 units/mL
acid phosphatase in 50 mM ammonium acetate pH 4.0) was added to the remaining homogenate
and incubated at 37°C for 1 h in water bath. After incubation, the homogenate was centrifuged
at 13,200 rpm for 10 min.
Solid phase extraction procedure (6)
Solid-phase extraction columns (1.0 mL, 200 mg BOND ELUT-C18 Varian, Harbor City, CA)
were placed on a vacuum elution manifold (20-SPE System, Waters, Milford, MA). The
cartridges were rinsed with 500 μL of methanol, and then conditioned with 500 μL of 150 mM
ammonium acetate (pH 5.0). After loading 200 μL of 150 mM ammonium acetate (pH 5.0) to
the cartridge, 360 μL of centrifuged blank, calibrator, QC, or patient tissue homogenate was
added to the SPE column. Tissue homogenates were allowed to pass through the column bed
with minimal suction (1–3 mmHg). The column was further washed with 900 μL of 100 mM
ammonium acetate buffer (pH 7.0) and then suctioned to dryness for 2 min using 10–15 mmHg
of vacuum. The retained drugs were then eluted with 500 μL of methanol. The eluent solution
was evaporated to dryness under a gentle nitrogen stream at 45°C, and the residue was
reconstituted with 50 μL of reconstitution solution (3% acetonitrile–1% acetic acid in HPLC
water). The resulting solutions were sonicated for 30 s, carefully vortexed for 30 s, and
centrifuged at 13,200 rpm for 10 min. The supernatants were transferred to 200-μL HPLC
autosampler vials (Microvials, Agilent), and 5 μL was injected onto the column.
Chromatography and LC–MS conditions
Chromatographic separation was achieved with gradient elution on a Varian Polaris 3C18-A
analytical column, (3.0 μm particle size) protected by a Polar RP guard cartridge. Two mobile
phases were used: Mobile phase A was composed of 0.1% formic acid in HPLC water,
measured pH 2.5. Mobile phase B was composed of 0.1 % formic acid in acetonitrile. A linear
gradient was programmed from 3% to 90% mobile phase B over 5.5 min with holding until
7.5 min and from 90% to 3% mobile phase B between 7.5 min and 7.7 min with holding until
13.0 min. The analysis was performed at room temperature with a gradient mobile phase flow
rate of 0.2 mL/min over the 13 min run time. No carryover was found when the TNF
concentrations were within the range of the calibrators. The detector settings were: ESI with
the stainless steel spray needle, positive polarity ionization; detector voltage, 1.5 kV; Curved
Desolvation Line (CDL) temperature, 250°C; Heat block temperature, 200°C; nebulizing gas
flow, 1.5 L/min; drying gas on. Two different mass-to-charge ratios in positive ion mode were
used to monitor the intensity during elution of the analytes; 288.05 m/z-TNF, 271.00 m/z-
tolbutamide (IS). The positive ion mode was chosen for this assay, as an initial study indicated
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a more sensitive response than with the negative ion mode. The low pH of mobile phase was
necessary for adequate analyte retention.
Validation of the method (11,12)
Validation of the analytical method included evaluation of calibration curve performance,
recovery, intra- and inter-day accuracy, precision of the method, stability of the analytes at
various test conditions (determined by TNF and TNF-DP QC performance), evaluation of
specificity and matrix effect, and comparing differences between fresh and frozen tissue.
Inter- and intra-day accuracy and precision for the assay were characterized by QC performance
(four concentrations for TNF and three concentrations for TNF-DP) on three separate days
using three replicates each day. Concentrations for TNF QCs included 1 ng/mL (equivalent to
the lower limit of quantification of the assay), 3 ng/mL, 150 ng/mL, and 750 ng/mL. Precision
was quantified as the coefficient of variation (CV %) within a single run (intra-day) and
between different runs (inter-day). Accuracy was quantified as the percentage of deviation
between nominal and measured concentrations. The lower limit of quantification was
determined as a signal-to-noise ratio of 5:1 with CVs of accuracy and precision of less than
20% at this concentration.
The stability of TNF and TNF-DP in tissue was also investigated using the medium (150 ng/
mL) and high (750ng/mL) QCs in triplicate. Short-term stability testing was performed by
leaving stock solutions at room temperature for 6 h and spiked tissue samples at room
temperature for 24 h prior to extraction. Long term stability testing was performed by leaving
stock solutions and spiked tissue samples at −70°C for two months. Stabilities of TNF and
TNF-DP during sample handling were evaluated by subjecting samples to three freeze-thaw
cycles. Finally, testing was performed to verify stabilities of TNF and TNF-DP when held in
an autosampler for 72 h.
Specificity was tested using tissues from six different women. Matrix effects were assessed by
calculating the response ratio between analytes, with and without matrix, and by calculating
the % differences between fresh and frozen tissue at one standard concentration of 500 ng/mL.
Analysis of clinical samples
We examined the applicability of the method by analyzing tissue collected from HIV-negative
subjects after a single dose of 1% TNF vaginal gel.
Results
Linearity
The peak area ratios of the calibration standards to the internal standard were proportional to
the concentration of each drug in tissue over the range tested. The linear range for TNF was
1–1,000 ng/mL, and the regression coefficients (r2) were all greater than 0.999. Calibration
parameters of slope and intercept were calculated.
Selectivity
Figure 2 shows a representative chromatogram of blank tissue (A); the approximate retention
times of TNF and IS were 3.7 min and 7.5 min, respectively. No other peak was interfered with
the peak of TNF or IS in this method.
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The intra- and inter-day accuracy and precision (CV %) of TNF and TNF-DP are listed in Table
I. The accuracy of TNF ranged from 89.7 to 109.4% with a mean of 99.1%. Throughout the
concentration range of the control samples, the mean intra- and inter-assay precision for TNF
remained less than 10.9%. All the accuracies and precisions of the analytes were within the
acceptable range according to bioanalytical method validation guidelines (11).
The limit of quantification
The low limit of quantification for TNF was 1 ng/mL. Accuracy and precision at the lower
limit of quantification were less than 10.9% for TNF and, therefore, within the acceptable range
(11).
Recovery
The absolute recovery of TNF from tissue extracted using SPE was calculated by comparing
peak areas of extracted QC samples to peak areas of QC sample concentrations spiked into
blank tissue after the extraction was performed. This method was used to account for matrix
effects with the MS detection. This extraction method resulted in a clean baseline (Figure 2A).
Table II shows the recovery results and a mean recovery of 74.1% using three QC samples for
TNF and 70.0% for IS.
Stability
Drug stability in biological fluids is a function of the sample storage conditions, the chemical
properties of the drug, the matrix, and the container system (11). The stability of TNF and
TNF-DP were evaluated under conditions reflecting situations likely to be encountered during
actual sample handling and analysis. TNF and TNF-DP were found to be stable in stock
solutions during sample collection and handling, after short and long-term storage, after three
freeze-thaw cycles, and during the analytical process. Table III demonstrates that all results in
the stability testing of TNF and TNF-DP were within the acceptance range of ± 15% deviation
from the nominal concentration.
Matrix effect
The approach used to assess possible matrix differences among different tissues was evaluated
by measuring TNF response with and without matrix as previously described (12). Mean (CV)
matrix effect (n = 5) for TNF was 83.1% (6.5%). Although ionization of TNF was suppressed
with the tissue matrix, the matrix effect was consistent in the five different tissue samples
tested.
Application of the method
Figure 2B–2C show representative chromatograms from clinical samples 2 and 24 h after
administration of TNF gel preparation. No other interfering peaks were found.
Discussion
This paper details the validation of a most accurate, sensitive, and selective method for
measuring TNF in human tissue using LC–MS. Although several methods for measuring TNF
in blood plasma using HPLC or LC–MS–MS have been reported (3–10), this method is the
first to measure TNF in tissue samples at a low limit of quantification (1 ng/mL).
We have previously published a validated method of measuring TNF in blood plasma using
LC–UV (6). The solid-phase extraction procedure utilized in this plasma method was also
found to be optimal for MS detection of tissue concentrations.
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This method required careful optimization of the MS conditions, including ionization mode
and the LC conditions (column and mobile phase composition and flow). Because TNF can
accept a proton from an acidic mobile phase, positive detection mode with a mobile phase
containing 0.1% formic acid was chosen. With optimization of the gradient conditions, and the
addition of a long re-equilibration time, TNF's retention time remained consistent. An acidic
reconstitution solution was used to further enhance ionization. To retain TNF, we tested three
different columns; Atlantis C18 (Waters), Zorbax C18 (Agilent), and Polaris 3C18-A (Varian).
With the exception of the Varian Polaris 3C18-A column, all columns resulted in an
unacceptable early elution of TNF. The Varian Polaris 3C18-A column eluted TNF at
approximately 3.5 min with excellent peak shape.
Tolbutamide was chosen as IS due to its similar behavior to TNF when subjected to the solid-
phase extraction procedure and its good resolution from TNF on the chromatogram. The
amount of tolbutamide was selected based on recovery and reproducibility in the assay.
Tolbutamide was added to tissues before homogenization to compensate for any loss of sample
during this process.
Complete homogenization of tissues was critical to extracting all intracellular TNF and
obtaining accurate and precise protein concentrations. Homogenization conditions were
optimized for speed and duration of the cycle, in addition to the type of homogenization tubes.
Complete homogenization required approximately ten cycles of a 60 s run. Five min of rest
was provided between runs to prevent overheating of the homogenate.
Phosphorylation of TNF occurs rapidly in cells, and in vitro data suggest that most of the
intracellular drug exists as the diphosphate form (9). Due to the small biopsy sample sizes, this
method was designed to measure total TNF drug concentration (extracellular + intracellular)
in tissues using enzymatic hydrolysis with phosphatase. The conditions for enzymatic
hydrolysis were optimized for the amount of phosphatase, incubation time, and temperature.
The optimized condition yielded greater than 98% cleavage of TNF diphosphate.
This method has been fully validated. Intra- and inter-day accuracy and precision at LLOQ,
low, medium, and high concentration were acceptable and within 15% of nominal (Table I).
TNF was acceptably stable under all the storage conditions tested. The mean extraction
efficiency of TNF was 74.1%, and the mean matrix effect was 83.1%, and consistent between
the different tissue samples evaluated. Assay specificity was evaluated in six different tissues.
The responses of TNF from fresh and frozen tissues were compared in six different tissues,
and the maximum difference was 8.3%. Calibration curves were found linear over the range
of 1–1000 ng/mL (r2 > 0.998).
Conclusion
A SPE extraction method followed by an automated and optimized LC–MS method has been
developed for the analysis of total TNF in human vaginal tissue. This method is sensitive,
accurate, and precise and will assist in the drug development process. This approach can be
used to assess the pharmacokinetics of TNF in human vaginal tissue.
Acknowledgments
This work was supported by Conrad, the UNC Center for AIDS Research (AI50410), AI54980 (ADMK) and a Korea
Research Foundation Grant (KRF-2005-214) funded by the Korean Government (MOEHRD). The authors are
indebted to Dr. Kan Lu, and the following surgeons in the Division of Urogynecology, Department of Obstetrics and
Gynecology, at the University of North Carolina at Chapel Hill for their assistance in the collection of vaginal tissue:
Thao Nguyen, Elizabeth Geller, and Jennifer Wu.
Choi et al. Page 6














1. Porshe DJ. TNF disoproxil fumarate (Viread). J. Association of Nurses in AIDS care. J Assoc Nurses
AIDS care 2002;13(3):100–102. [PubMed: 12064015]
2. Mayer KH. Safety and tolerability of TNF vaginal gel in abstinent and sexually active HIV-infected
and uninfected women. AIDS 2006;20(4):543–551. [PubMed: 16470118]
3. Jullien V, Treluyer JM, Pons G, Rey E. Determination of TNF in human plasma by high-performance
liquid chromatography with spectrofluorimetric detection. J Chromatogr B 2003;785:377–381.
4. Sparidans RW, Crommemtuyn KML, Schellens JHM, Beijnen JH. Liquid chromatographic assay for
the antiviral nucleotide analogue TNF in plasma using derivatization with chloroacetaldehyde. J
Chromatogr B 2003;791:227–233.
5. Sentenac S, Fernandez C, Thuillier A, Lechat P, Aymard G. Sensitive determination of TNF in human
plasma samples using reversed-phase liquid chromatography. J Chromatogr B 2003;793:317–324.
6. Rezk NL, Crutchley RD, Kashuba ADM. Simultaneous quantification of emtricitabine and TNF in
human plasma using high-performance liquid chromatography after solid phase extraction. J
Chromatogr B 2005;822:201–208.
7. Bezy V, Morin P, Couerbe P, Leleu G, Agrofoglio L. Simultaneous analysis of several antiretroviral
nucleosides in rat-plasma by high-performance liquid chromatography with UV using acetic acid/
hydroxylamine buffer Test of this new volatile medium-pH for HPLC–ESI-MS/MS. J Chromatogr B
2005;821:132–143.
8. Delahunty T, Bushman L, Fetcher CV. Sensitive assay for determining plasma TNF concentrations by
LC/MS/MS. J Chromatogr B 2006;830:6–12.
9. King T, Bushman L, Kiser J, Anderson PL, Ray M, Delahunty T, Fletcher CV. Liquid chromatography–
tandem mass spectrometric determination of TNF-diphosphate in human peripheral blood
mononuclear cells. J Chromatogr B 2006;843:147–156.
10. Barkil ML, Gagnieu MC, Guitton J. Relevance of a combined UV and single mass spectrometry
detection for the determination of TNF in human plasma by HPLC in therapeutic drug monitoring.
J Chromatogr B 2007;854:192–197.
11. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry,
Bioanalytical Method Validation. 2001.
12. Bansal S, Destefano A. Key elements of bioanalytical method validation for small molecules. The
AAPS Journal 2007;9:109–114.
Choi et al. Page 7














The chemical structure of TNF (A), and TNF diphosphate (B) tolbutamid (C).
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Representative LC-MS chromatograms of TNF in vaginal tissue samples: (A) blank tissues
and (B) after 2 h and (C) 24 h administration of 1% TNF gel.
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Table II
Recovery (%) of TNF in Human Tissue*
Test of Recovery Low QC† Medium QC‡ High QC§
Recovery (%) 74.4 ± 2.6 70.0 ± 5.4 78.0 ± 0.8
*
Data are mean values ± SD (n = 3).
†
Low QC is 3 ng/mL
‡
Medium QC is 150 ng/mL
§
High QC is 750 ng/mL.
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Table III
Stability of TNF and TNF-DP in Human Tissue*
Stability of TNF (%) Stability of TNF-DP (%)
Test of stability Medium QC† High QC‡ Medium QC† High QC‡
Freeze/Thaw 98.2 ± 5.4 90.2 ± 1.8 95.3 ± 5.3 99.2 ± 3.6
Short-term§ 102.6 ± 0.8 101.0 ± 1.4 88.5 ± 1.5 98.5 ± 1.6
Long-term** 106.6 ± 7.9 99.09 ± 2.4 104.49 ± 2.9 102.0 ± 2.5
Post-preparative 92.3 ± 8.1 86.2 ± 5.2 98.4 ± 6.8 81.8 ± 1.4
Stock solution 103.6 ± 4.9 100.4 ± 0.8
*
Data are mean values ± SD (n = 3).
†
Medium QC is 150 ng/mL.
‡
High QC is 750 ng/mL.
§
Short-term stability was tested after 24 h at room temperature.
**
Long-term stability was tested after two months at −70°C.
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